The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Immuno-oncology Therapy-Global Market Insights and Sales Trends 2025
Synopsis
Immuno-oncology therapy is a type of cancer treatment that harnesses the body's immune system to target and destroy cancer cells. It includes therapies such as immune checkpoint inhibitors, cancer vaccines, and adoptive T cell therapies.
The global Immuno-oncology Therapy market size is expected to reach US$ 1648.7 million by 2029, growing at a CAGR of 4.5% from 2023 to 2029. The market is mainly driven by the significant applications of Immuno-oncology Therapy in various end use industries. The expanding demands from the Hospitals, Ambulatory Surgical Center and Others,, are propelling Immuno-oncology Therapy market. Monoclonal Antibodies, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Immune Checkpoint Inhibitors segment is estimated at % CAGR for the next seven-year period.
The market for immuno-oncology therapy is driven by the growing interest in personalized and targeted cancer treatments and the need for innovative therapies with fewer side effects. The market's growth is also influenced by the approval of new immuno-oncology drugs and ongoing research in cancer immunotherapy.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Immuno-oncology Therapy, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Immuno-oncology Therapy market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Immuno-oncology Therapy market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Immuno-oncology Therapy sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Immuno-oncology Therapy covered in this report include Amgen, AstraZeneca, Bristol-Myers Squibb, Eli-Lilly, Roche, GlaxoSmithKline, Janssen Biotech, Merck and Novartis, etc.
The global Immuno-oncology Therapy market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Amgen
AstraZeneca
Bristol-Myers Squibb
Eli-Lilly
Roche
GlaxoSmithKline
Janssen Biotech
Merck
Novartis
Pfizer
Sanofi
Spectrum Pharmaceuticals
Takeda
BioNTech SE
Allogene Therapeutics
IMAB-I-Mab Biopharma Co., Ltd.
Arcus Biosciences
Gritstone Oncology
Autolus Therapeutics
Rubius Therapeutics
Global Immuno-oncology Therapy market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Immuno-oncology Therapy market, Segment by Type:
Monoclonal Antibodies
Immune Checkpoint Inhibitors
Immune System Modulators
Cancer Vaccines
Global Immuno-oncology Therapy market, by Application
Hospitals
Ambulatory Surgical Center
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Immuno-oncology Therapy companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Immuno-oncology therapy is a type of cancer treatment that harnesses the body's immune system to target and destroy cancer cells. It includes therapies such as immune checkpoint inhibitors, cancer vaccines, and adoptive T cell therapies.
The global Immuno-oncology Therapy market size is expected to reach US$ 1648.7 million by 2029, growing at a CAGR of 4.5% from 2023 to 2029. The market is mainly driven by the significant applications of Immuno-oncology Therapy in various end use industries. The expanding demands from the Hospitals, Ambulatory Surgical Center and Others,, are propelling Immuno-oncology Therapy market. Monoclonal Antibodies, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Immune Checkpoint Inhibitors segment is estimated at % CAGR for the next seven-year period.
The market for immuno-oncology therapy is driven by the growing interest in personalized and targeted cancer treatments and the need for innovative therapies with fewer side effects. The market's growth is also influenced by the approval of new immuno-oncology drugs and ongoing research in cancer immunotherapy.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Immuno-oncology Therapy, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Immuno-oncology Therapy market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Immuno-oncology Therapy market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Immuno-oncology Therapy sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Immuno-oncology Therapy covered in this report include Amgen, AstraZeneca, Bristol-Myers Squibb, Eli-Lilly, Roche, GlaxoSmithKline, Janssen Biotech, Merck and Novartis, etc.
The global Immuno-oncology Therapy market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Amgen
AstraZeneca
Bristol-Myers Squibb
Eli-Lilly
Roche
GlaxoSmithKline
Janssen Biotech
Merck
Novartis
Pfizer
Sanofi
Spectrum Pharmaceuticals
Takeda
BioNTech SE
Allogene Therapeutics
IMAB-I-Mab Biopharma Co., Ltd.
Arcus Biosciences
Gritstone Oncology
Autolus Therapeutics
Rubius Therapeutics
Global Immuno-oncology Therapy market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Immuno-oncology Therapy market, Segment by Type:
Monoclonal Antibodies
Immune Checkpoint Inhibitors
Immune System Modulators
Cancer Vaccines
Global Immuno-oncology Therapy market, by Application
Hospitals
Ambulatory Surgical Center
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Immuno-oncology Therapy companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Immuno-oncology Therapy
1.1 Immuno-oncology Therapy Market Overview
1.1.1 Immuno-oncology Therapy Product Scope
1.1.2 Immuno-oncology Therapy Market Status and Outlook
1.2 Global Immuno-oncology Therapy Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Immuno-oncology Therapy Market Size by Region (2018-2029)
1.4 Global Immuno-oncology Therapy Historic Market Size by Region (2018-2023)
1.5 Global Immuno-oncology Therapy Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Immuno-oncology Therapy Market Size (2018-2029)
1.6.1 North America Immuno-oncology Therapy Market Size (2018-2029)
1.6.2 Europe Immuno-oncology Therapy Market Size (2018-2029)
1.6.3 Asia-Pacific Immuno-oncology Therapy Market Size (2018-2029)
1.6.4 Latin America Immuno-oncology Therapy Market Size (2018-2029)
1.6.5 Middle East & Africa Immuno-oncology Therapy Market Size (2018-2029)
2 Immuno-oncology Therapy Market by Type
2.1 Introduction
2.1.1 Monoclonal Antibodies
2.1.2 Immune Checkpoint Inhibitors
2.1.3 Immune System Modulators
2.1.4 Cancer Vaccines
2.2 Global Immuno-oncology Therapy Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Immuno-oncology Therapy Historic Market Size by Type (2018-2023)
2.2.2 Global Immuno-oncology Therapy Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Immuno-oncology Therapy Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Immuno-oncology Therapy Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Immuno-oncology Therapy Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Immuno-oncology Therapy Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Immuno-oncology Therapy Revenue Breakdown by Type (2018-2029)
3 Immuno-oncology Therapy Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Ambulatory Surgical Center
3.1.3 Others
3.2 Global Immuno-oncology Therapy Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Immuno-oncology Therapy Historic Market Size by Application (2018-2023)
3.2.2 Global Immuno-oncology Therapy Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Immuno-oncology Therapy Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Immuno-oncology Therapy Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Immuno-oncology Therapy Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Immuno-oncology Therapy Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Immuno-oncology Therapy Revenue Breakdown by Application (2018-2029)
4 Immuno-oncology Therapy Competition Analysis by Players
4.1 Global Immuno-oncology Therapy Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Immuno-oncology Therapy as of 2022)
4.3 Date of Key Players Enter into Immuno-oncology Therapy Market
4.4 Global Top Players Immuno-oncology Therapy Headquarters and Area Served
4.5 Key Players Immuno-oncology Therapy Product Solution and Service
4.6 Competitive Status
4.6.1 Immuno-oncology Therapy Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Amgen
5.1.1 Amgen Profile
5.1.2 Amgen Main Business
5.1.3 Amgen Immuno-oncology Therapy Products, Services and Solutions
5.1.4 Amgen Immuno-oncology Therapy Revenue (US$ Million) & (2018-2023)
5.1.5 Amgen Recent Developments
5.2 AstraZeneca
5.2.1 AstraZeneca Profile
5.2.2 AstraZeneca Main Business
5.2.3 AstraZeneca Immuno-oncology Therapy Products, Services and Solutions
5.2.4 AstraZeneca Immuno-oncology Therapy Revenue (US$ Million) & (2018-2023)
5.2.5 AstraZeneca Recent Developments
5.3 Bristol-Myers Squibb
5.3.1 Bristol-Myers Squibb Profile
5.3.2 Bristol-Myers Squibb Main Business
5.3.3 Bristol-Myers Squibb Immuno-oncology Therapy Products, Services and Solutions
5.3.4 Bristol-Myers Squibb Immuno-oncology Therapy Revenue (US$ Million) & (2018-2023)
5.3.5 Eli-Lilly Recent Developments
5.4 Eli-Lilly
5.4.1 Eli-Lilly Profile
5.4.2 Eli-Lilly Main Business
5.4.3 Eli-Lilly Immuno-oncology Therapy Products, Services and Solutions
5.4.4 Eli-Lilly Immuno-oncology Therapy Revenue (US$ Million) & (2018-2023)
5.4.5 Eli-Lilly Recent Developments
5.5 Roche
5.5.1 Roche Profile
5.5.2 Roche Main Business
5.5.3 Roche Immuno-oncology Therapy Products, Services and Solutions
5.5.4 Roche Immuno-oncology Therapy Revenue (US$ Million) & (2018-2023)
5.5.5 Roche Recent Developments
5.6 GlaxoSmithKline
5.6.1 GlaxoSmithKline Profile
5.6.2 GlaxoSmithKline Main Business
5.6.3 GlaxoSmithKline Immuno-oncology Therapy Products, Services and Solutions
5.6.4 GlaxoSmithKline Immuno-oncology Therapy Revenue (US$ Million) & (2018-2023)
5.6.5 GlaxoSmithKline Recent Developments
5.7 Janssen Biotech
5.7.1 Janssen Biotech Profile
5.7.2 Janssen Biotech Main Business
5.7.3 Janssen Biotech Immuno-oncology Therapy Products, Services and Solutions
5.7.4 Janssen Biotech Immuno-oncology Therapy Revenue (US$ Million) & (2018-2023)
5.7.5 Janssen Biotech Recent Developments
5.8 Merck
5.8.1 Merck Profile
5.8.2 Merck Main Business
5.8.3 Merck Immuno-oncology Therapy Products, Services and Solutions
5.8.4 Merck Immuno-oncology Therapy Revenue (US$ Million) & (2018-2023)
5.8.5 Merck Recent Developments
5.9 Novartis
5.9.1 Novartis Profile
5.9.2 Novartis Main Business
5.9.3 Novartis Immuno-oncology Therapy Products, Services and Solutions
5.9.4 Novartis Immuno-oncology Therapy Revenue (US$ Million) & (2018-2023)
5.9.5 Novartis Recent Developments
5.10 Pfizer
5.10.1 Pfizer Profile
5.10.2 Pfizer Main Business
5.10.3 Pfizer Immuno-oncology Therapy Products, Services and Solutions
5.10.4 Pfizer Immuno-oncology Therapy Revenue (US$ Million) & (2018-2023)
5.10.5 Pfizer Recent Developments
5.11 Sanofi
5.11.1 Sanofi Profile
5.11.2 Sanofi Main Business
5.11.3 Sanofi Immuno-oncology Therapy Products, Services and Solutions
5.11.4 Sanofi Immuno-oncology Therapy Revenue (US$ Million) & (2018-2023)
5.11.5 Sanofi Recent Developments
5.12 Spectrum Pharmaceuticals
5.12.1 Spectrum Pharmaceuticals Profile
5.12.2 Spectrum Pharmaceuticals Main Business
5.12.3 Spectrum Pharmaceuticals Immuno-oncology Therapy Products, Services and Solutions
5.12.4 Spectrum Pharmaceuticals Immuno-oncology Therapy Revenue (US$ Million) & (2018-2023)
5.12.5 Spectrum Pharmaceuticals Recent Developments
5.13 Takeda
5.13.1 Takeda Profile
5.13.2 Takeda Main Business
5.13.3 Takeda Immuno-oncology Therapy Products, Services and Solutions
5.13.4 Takeda Immuno-oncology Therapy Revenue (US$ Million) & (2018-2023)
5.13.5 Takeda Recent Developments
5.14 BioNTech SE
5.14.1 BioNTech SE Profile
5.14.2 BioNTech SE Main Business
5.14.3 BioNTech SE Immuno-oncology Therapy Products, Services and Solutions
5.14.4 BioNTech SE Immuno-oncology Therapy Revenue (US$ Million) & (2018-2023)
5.14.5 BioNTech SE Recent Developments
5.15 Allogene Therapeutics
5.15.1 Allogene Therapeutics Profile
5.15.2 Allogene Therapeutics Main Business
5.15.3 Allogene Therapeutics Immuno-oncology Therapy Products, Services and Solutions
5.15.4 Allogene Therapeutics Immuno-oncology Therapy Revenue (US$ Million) & (2018-2023)
5.15.5 Allogene Therapeutics Recent Developments
5.16 IMAB-I-Mab Biopharma Co., Ltd.
5.16.1 IMAB-I-Mab Biopharma Co., Ltd. Profile
5.16.2 IMAB-I-Mab Biopharma Co., Ltd. Main Business
5.16.3 IMAB-I-Mab Biopharma Co., Ltd. Immuno-oncology Therapy Products, Services and Solutions
5.16.4 IMAB-I-Mab Biopharma Co., Ltd. Immuno-oncology Therapy Revenue (US$ Million) & (2018-2023)
5.16.5 IMAB-I-Mab Biopharma Co., Ltd. Recent Developments
5.17 Arcus Biosciences
5.17.1 Arcus Biosciences Profile
5.17.2 Arcus Biosciences Main Business
5.17.3 Arcus Biosciences Immuno-oncology Therapy Products, Services and Solutions
5.17.4 Arcus Biosciences Immuno-oncology Therapy Revenue (US$ Million) & (2018-2023)
5.17.5 Arcus Biosciences Recent Developments
5.18 Gritstone Oncology
5.18.1 Gritstone Oncology Profile
5.18.2 Gritstone Oncology Main Business
5.18.3 Gritstone Oncology Immuno-oncology Therapy Products, Services and Solutions
5.18.4 Gritstone Oncology Immuno-oncology Therapy Revenue (US$ Million) & (2018-2023)
5.18.5 Gritstone Oncology Recent Developments
5.19 Autolus Therapeutics
5.19.1 Autolus Therapeutics Profile
5.19.2 Autolus Therapeutics Main Business
5.19.3 Autolus Therapeutics Immuno-oncology Therapy Products, Services and Solutions
5.19.4 Autolus Therapeutics Immuno-oncology Therapy Revenue (US$ Million) & (2018-2023)
5.19.5 Autolus Therapeutics Recent Developments
5.20 Rubius Therapeutics
5.20.1 Rubius Therapeutics Profile
5.20.2 Rubius Therapeutics Main Business
5.20.3 Rubius Therapeutics Immuno-oncology Therapy Products, Services and Solutions
5.20.4 Rubius Therapeutics Immuno-oncology Therapy Revenue (US$ Million) & (2018-2023)
5.20.5 Rubius Therapeutics Recent Developments
6 North America
6.1 North America Immuno-oncology Therapy Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Immuno-oncology Therapy Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Immuno-oncology Therapy Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Immuno-oncology Therapy Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Immuno-oncology Therapy Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Immuno-oncology Therapy Market Dynamics
11.1 Immuno-oncology Therapy Industry Trends
11.2 Immuno-oncology Therapy Market Drivers
11.3 Immuno-oncology Therapy Market Challenges
11.4 Immuno-oncology Therapy Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
